|
市場調查報告書
結核治療市場動向
Tuberculosis: Trends, Challenges, and Opportunities in a Resurging Market
|
本報告已在2011年12月21日停止出版。
許多開發中國家的結核病流行主要是因為與HIV的相互感染以及多發抗藥性結核病的出現與擴散的緣故。感染症專家甚至認為在結核感染源完全被撲滅之前，全球各地仍舊處在結核傳染的威脅下。
廣泛調查醫療業界的美國專業市調公司 Decision Resources Inc. （總公司：麻州），調查與分析結核治療動向，並有系統地出版綜合報告書 "Tuberculosis: Trends, Challenges, and Opportunities in a Resurging Market" 。
此報告書使用18頁的篇幅，除了分別從疾病、病因學及病態生理學等層面分析結核病，也探討治療法與製藥企業的課題與機會等。此報告書的概略架構如下所示。
結核的概要
- 結核的疾病學
- 結核的病態生理學
- 臨床結果
- 結核的風險要素
- 其他免疫障礙
全球罹患率的動向與結核的發病
- 概要
- 結核感染的促進要素
- 全球多發抗藥性結核病（MDR-TB）的發病與罹患
治療與治療計畫
結核治療市場的機會
Abstract
TB is epidemic in many developing countries, owing in part to co-infection
with HIV and the emergence and spread of multidrug-resistant strains of TB
(MDR-TB). The general consensus among infectious disease experts is that the
entire globe will remain at risk for TB epidemics until active TB transmission
is eradicated. But TB drug development faces significant challenges, and for
the past 30 years, the pipeline of novel therapeutics for treatment of TB has
been sparse. Now, however, given various factors--the fact that TB
transmission has been on the rise since the early 1980s, the emerging threat
of MDR-TB, and TB's role as an opportunistic infection in HIV
patients--government agencies, nongovernmental organizations (NGOs), and
pharmaceutical companies have a renewed interest in developing drugs for TB.
In 2000, several foundations, government agencies, and NGOs established the
Global Alliance for TB Drug Development (TB Alliance). In this report, we
review TB epidemiology, etiology and pathophysiology, resistance patterns, and
treatment approaches, and we highlight challenges and opportunities for the
pharmaceutical industry
Table of Contents
- Contents Overview of Tuberculosis
- Etiology of Tuberculosis
- Pathophysiology of Tuberculosis
- Clinical Outcomes
- Risk Factors Associated with TB
- Co-Infection with HIV
- Other Immunocompromising Diseases
- Multidrug-Resistant Tuberculosis
- Trends in Global Prevalence and Incidence of TB
- Overview
- Drivers of TB Transmission
- Social Structure
- Health Care Infrastructure
- Immigration
- Global Incidence and Prevalence of MDR-TB
- Prevalence of MDR-TB in Newly Diagnosed TB Cases
- Prevalence of MDR-TB in Previously Treated TB Cases
- Therapies and Therapeutic Programs
- Current Therapies
- Therapeutic Programs for Treatment of TB
- Emerging Therapies
- Opportunities in the TB Market
|
